3SBio Inc. (FRA:83B)

Market Cap	5.33B
Revenue (ttm)	1.21B
Net Income (ttm)	276.61M
Shares Out	n/a
EPS (ttm)	0.11
PE Ratio	19.28
Forward PE	18.33
Dividend	0.03 (1.37%)
Ex-Dividend Date	Jul 22, 2024

Volume	150
Average Volume	1,033
Open	2.100
Previous Close	2.160
Day's Range	2.100 - 2.140
52-Week Range	0.570 - 2.440
Beta	n/a
RSI	65.54
Earnings Date	May 9, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 5,577
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 83B

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY